In February 2019, I attended a meeting of the Advisory Committee for Immunization Practices (ACIP) for the first time. This post describes my observations from the two-day ACIP meeting process.
Generally, the meeting taught me that the process the committee goes through is highly deliberative, data-intensive, and the committee pays close attention to safety and maximizing benefits. Though no process is perfect, the meeting increased my confidence in the decision-making process behind the vaccines recommendations that apply to my children.
Numerous anti-vaccine group attended added some excitement and some stress, but was, from a standpoint of vaccine policy-making, largely irrelevant.
I am initially, a public administration scholar – I wrote my dissertation on agency accountability, taught the Federal Advisory Committee Act multiple times, and teach almost annually about agency decision making. This made me very interested in the committee’s process. I also knew in advance that there will be – as there has been in several previous meeting – numerous anti-vaccine activists, and was curious to see their interaction with the meeting in reality.
Initially, I thought I would describe in detail what was addressed in the meeting, but I think that would make this post too long. For those who are interested, here is the agenda for the February 2019 ACIP meeting (pdf).
Instead, I will offer my observations about the process. I will mention that the only things voted on in this meeting were related to Japanese encephalitis vaccine and anthrax vaccine. The committee voted to make some changes to the language of the recommendation of the Japanese encephalitis vaccine for travelers to clarify it, but not changes to the actual recommendation, changes to the timeline for adult priming series (the initial vaccine series) from a 28-day interval to an interval that can span 7-28 days, and expanding the age for recommending a booster for children and putting that recommendation on equal footing to the recommendation for an adult booster.
With respect to anthrax vaccines, the committee recommended giving a booster dose to high-risk people (like first responders) who are not currently exposed but may be at risk of exposure, if they want it.
Everything else discussed was informational – some of it as part of the process of preparing for future votes (Like whether to extend the recommendation for HPV vaccines to include those 26-45), some of it as part of ongoing monitoring (like the examination of flu vaccines’ data). Continue reading “February 2019 ACIP Meeting – the process for vaccine recommendations”